Key result
Direct oral anticoagulants are now widely used for the prophylaxis and treatment of cancer-associated venous thromboembolism.
Why the study?
DOACs are now widely used for venous thromboembolism management including cancer-associated thrombosis, prompting a summary of recent data, guidelines, challenges, and updates.
What is the role of direct oral anticoagulants (DOACs) in the management and prophylaxis of cancer-associated venous thromboembolism?
What is the role of direct oral anticoagulants (DOACs) in the management and prophylaxis of cancer-associated venous thromboembolism?
This review summarizes the 2019 landscape of DOAC use for VTE prophylaxis and treatment in patients with cancer-associated thrombosis.
Answers are grounded in this paper and cite their sources.
DOACs may inform cancer VTE management; review extends data synthesis but leaves practice changes open pending RCTs.
Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and updates as well as the current place for DOACs on the emerging cancer-associated VTE management landscape.
No takes yet. Share an insight, caveat, or question.
Ramacciotti et al. (2019) studied this question. Direct oral anticoagulants are now widely used for the prophylaxis and treatment of cancer-associated venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: